BPC-157 dosage and experimental units
The unit and the study subject have to travel with the amount. The literature supplies experimental quantities and no validated human regimen.
Per rat and per kilogram
The transected Achilles tendon experiment lists 10 microg, 10 ng or 10 pg per rat. The gastric-ulcer experiment used 400 ng/kg and 800 ng/kg in rats. These are different experimental designs, with different ways of expressing the amount.
A microgram is one millionth of a gram, a nanogram one billionth, and a picogram one trillionth. The denominator matters as well: per rat describes a whole animal; per kilogram describes body weight. An amount detached from those particulars earns my distrust.
The very wide range reported in the tendon work deserves closer investigation. Choosing the smallest or the largest published figure would leave the human benefit-and-risk question unanswered.
Route and exposure
In the rat ulcer study, intramuscular administration outperformed delivery into the stomach. In the rat and dog pharmacokinetic study, intramuscular bioavailability was ~14-19% in rats and ~45-51% in dogs. These figures describe the fraction of an administered amount reaching the circulation in those animals.
A different route can change exposure, and a different species can change it again. Those differences make a body-weight calculation alone inadequate for establishing a human dose. Formal human pharmacokinetics remain unestablished.
Infusion and bladder quantities
The two-adult intravenous pilot used 10 mg then 20 mg by infusion. The interstitial-cystitis pilot used 10 mg delivered into the bladder during a procedure. These are reported study amounts, tied to their original participants and procedures.
The small reports did not validate a general human dose or a schedule. An amount supported only by a preliminary tolerability observation strikes me as insufficient for balancing benefit and harm across people.
Duration, stopping and handling
The animal repair studies followed the injury and the experimental treatment. The 2025 account of the human evidence describes three small pilot reports, alongside older development work under names such as PL 14736 and PLD-116. The earlier development reports provide no clear participant count or adequate long-term safety record in the current account.
A safe human duration, stopping rule and discontinuation-effect profile remain unestablished. The <30-minute elimination half-life in rats and dogs measures clearance of the original peptide in those species; it cannot set a human treatment interval.
Reported stability in gastric juice also leaves practical storage and reconstitution questions unanswered for clinical use. This page supplies no preparation instructions. The FDA and pharmacy record addresses a separate set of requirements.